Martin Abrahamson, MD
Endocrinology, Diabetes & Metabolism · Boston, MANPI 1336254226
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 85.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $43,384 and has fallen 99.6% since, to $156 in 2025. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $1657.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$41K
- Novo Nordisk AS$6K
- AstraZeneca$930
- Corcept Therapeutics$124
- Abbott$103
- Tandem Diabetes Care, Inc.$25
- plus $50 from 3 others
What the payments were for
- Consulting fees$27,19557%
- Travel & lodging$20,11542%
- Food & beverage$7342%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $40,920 |
| Novo Nordisk AS | 5 | $5,925 |
| AstraZeneca | 1 | $930 |
| Corcept Therapeutics | 1 | $124 |
| Abbott | 3 | $103 |
| Tandem Diabetes Care, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xultophy 100/3.6$28,822
- Ryzodeg 70/30$13,163
- Tresiba$3,400
- FARXIGA$930
- Korlym$124
How this compares
$48,076 in reported general payments places this provider in the 90th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 334 | $427,672 |
| TrulicityDulaglutide | 196 | $305,628 |
| JardianceEmpagliflozin | 174 | $229,164 |
| MounjaroTirzepatide | 76 | $104,464 |
| Tresiba Flextouch U-100Insulin Degludec | 118 | $59,581 |
| RybelsusSemaglutide | 44 | $56,755 |
| JanuviaSitagliptin Phosphate | 39 | $52,631 |
| FarxigaDapagliflozin Propanediol | 39 | $38,875 |
| TradjentaLinagliptin | 23 | $21,310 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $20,861 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 13 | $19,798 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $17,425 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $16,548 |
| Humalog Kwikpen U-100Insulin Lispro | 66 | $16,097 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $15,274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $40,920 | $504,225391 claims |
| AstraZenecaFarxiga | $930 | $38,87539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Boston
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Augusto Caballero-RoblesBoston$150K
- Osama HamdyBoston$117K
- Barbara KahnBoston$105K
- Naomi FisherBoston$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.